Tirzepatide

Tirzepatide is a dual GIP and GLP-1 receptor agonist primarily utilized for weight management and glycemic control in type 2 diabetes. While community users report a wide range of doses, clinician-tier protocols typically involve subcutaneous administration of 2.5 mg to 15 mg weekly. Users occasionally report side effects including edema, sleep disturbances, nausea, and injection-site reactions. Readers should note that the evidence base for off-label indications remains significantly thinner than the current discourse suggests, as many exploratory uses lack published results.

Half-life~5 days

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.94.71.24.12.34.0

Research Evidence

Evidence shape

Tirzepatide carries a high evidence tier, supported by robust clinical data for the treatment of obesity and type 2 diabetes. The research landscape is extensive, featuring over 200 registered trials and 27 blinded studies that establish its efficacy in metabolic regulation and weight management. While the clinical signal is strong for these primary indications, the vast majority of the 95 mapped indications remain exploratory or rely on single-trial data, indicating that the current evidence base is heavily concentrated on a few core metabolic outcomes rather than broad therapeutic application.

Depthhow much
227 registered trials
79 completed · 45 with posted results · 141 recruiting / active · combined n=32841
Breadthhow many areas
98 indications mapped
10 with results · 86 thin / exploratory · 1 animal-only · 71 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
27 blinded with results · 13 distinct sponsors · AE rows aggregated from 43 trials · 126 linked publications on registered trials
Breadth and depth245 rows captured
Human
direct clinical signal
230
Animal
translational support
12
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

+1 more use case below visualisation cap

Tirzepatide side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
High Purity Peptides
Hong Kong
400 mg×10
$130.00
$0.325/mg
2
Chimera Peptides
CN
600 mg×10
$199.00
$0.33/mg
3
Saiyan Med
US
600 mg×10
$244.00
$0.41/mg
4
Better Peptide
US
100 mg
$44.99
$0.45/mg
5
Peptixusa
US
100 mg
$58.00
$0.58/mg
6
Peptide TechnologiesCode GROUNDTRUTH
unknown
50 mg
$39.99
$0.8/mg

price offers can be sorted by column · 13 out-of-stock offers not shown

Some links are affiliate links. This never affects our rankings or inclusion.

1-6 of 228

Tirzepatide dosing & protocol

How Tirzepatide is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 82
Typical dose
5 mg2.5 mg – 15 mg
typical
0
10 mg
20 mg
30 mg
distribution of 50 reported doses · darker = more
Frequency
weekly
Route
subQ

In the trial data, tirzepatide was administered subcutaneously once weekly, with doses typically around 5 mg and ranging from 2.5 mg to 15 mg.

82 sources
Clinician practice
Doctor & published-protocol guidance · n = 4
Starting dose
2.5 mg2.5 mg – 15 mg
start
0
10 mg
20 mg
30 mg
distribution of 8 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
weekly
Route
subQ

Clinician practice typically uses 15 mg subcutaneously once weekly, with reported doses ranging from 2.5 mg to 15 mg weekly.

4 sources
Anecdotal
Community-reported real-world use · n = 176
Typical dose
2.5 mg300 µg – 30 mg
typical
0
10 mg
20 mg
30 mg
distribution of 197 reported doses · darker = more
Frequency
unspecified
Route
subQ

Doses range from 300 mcg to 30 mg subcutaneously, commonly beginning around 2.5 mg; a minority report weekly dosing such as 5 mg or 3.75 mg per week, while many do not specify a schedule.

176 sources

Regulatory safety notes

Warnings and precautions
  • • Acute Pancreatitis: Has been observed in patients treated with GLP-1 receptor agonists, or MOUNJARO. Discontinue if pancreatitis is suspected.
  • • Hypoglycemia with Concomitant Use of Insulin Secretagogues or Insulin: Concomitant use with an insulin secretagogue or insulin may increase the risk of hypoglycemia, including severe hypoglycemia. Reducing dose of insulin secretagogue or insulin may be necess…
  • • Hypersensitivity Reactions: Serious hypersensitivity reactions (e.g., anaphylaxis and angioedema) have been reported. Discontinue MOUNJARO if suspected and promptly seek medical advice.
  • • Acute Kidney Injury Due to Volume Depletion: Monitor renal function in patients reporting adverse reactions that could lead to volume depletion.
  • • Severe Gastrointestinal Adverse Reactions: Use has been associated with gastrointestinal adverse reactions, sometimes severe. MOUNJARO is not recommended in patients with severe gastroparesis.
  • • Diabetic Retinopathy Complications in Patients with a History of Diabetic Retinopathy: Monitor patients with a history of diabetic retinopathy for progression.
  • • Acute Gallbladder Disease: Has occurred in clinical trials. If cholelithiasis is suspected, gallbladder studies and clinical follow-up are indicated.
  • • Pulmonary Aspiration During General Anesthesia or Deep Sedation: Has been reported in patients receiving GLP-1 receptor agonists undergoing elective surgeries or procedures. Instruct patients to inform healthcare providers of any planned surgeries or procedur…
Contraindications
  • • MOUNJARO is contraindicated in
  • • patients with: A personal or family history of medullary thyroid carcinoma (MTC) or in
  • • patients with Multiple Endocrine Neoplasia syndrome type 2 (MEN 2) [see Warnings and Precautions (5.1) ] . Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO. Serious hypersensitivity rea…
  • • patients with Multiple Endocrine Neoplasia syndrome type 2. Known serious hypersensitivity to tirzepatide or any of the excipients in MOUNJARO.
Drug interactions
  • • MOUNJARO delays gastric emptying and has the potential to impact the absorption of concomitantly administered oral medications. (7.2)

Related peptides

SemaglutideRetatrutideSurvodutideAOD-9604CagrilintideOrforglipronLiraglutideExenatideTesamorelinEloralintideTesofensineMazdutide